All posts by imreal

Titaniam’s New Secure Analytic Vault Updates render Traditional Tokenization tools obsolete


Titaniam’s Vault is built for high-performance, petabyte-scale, analytic use cases and enables full-featured search and analytics without any decryption or detokenization.

Titaniam, Inc., the industry’s most advanced data protection and ransomware immunity platform, announced updates to its Vault. While Titaniam’s overall platform supports a variety of data security architectures, the Vault, in particular, follows a tokenization approach but moves organizations far beyond the limits of traditional tokenization towards a new paradigm where valuable data can be tokenized and remain fully usable for both business and rich analytic applications.

“With the Titaniam Vault and the new updates we are announcing, we can deliver all the benefits of traditional tokenization without the severe data usability and performance restrictions that organizations have had to live with in the past,” said Arti Raman, CEO and founder of Titaniam. “Titaniam’s Vault is built for high-performance, petabyte-scale, analytic use cases and enables full-featured search and analytics without any decryption or detokenization. This makes the Vault and all downstream systems utilizing vault data immune to insider threats and all data-related cyberattacks including double extortion ransomware.”

“The good news isn’t just limited to security teams,” added Raman. “Titaniam Vault is a game changer for privacy teams as well. With its ability to release data in all nine privacy preserving formats, including various forms of tokenization, whole or partial data masking, various forms of traditional and format-preserving encryption, as well as complete or partial redaction, Titaniam can send data to downstream applications according to the granular privacy policy and also support in-depth privacy audit and reporting as needed.”

While the original Titaniam Vault was already very powerful relative to traditional tokenization, the updated Vault can house both structured and unstructured data, including documents, images, voice, video, and other binaries. Secure structured data can support rich search and analytics with full data context. Enterprises can also build natively secure applications directly on top of the Vault. Unstructured files and content within them can be confidentially tagged and searched and can support a wide variety of secure data usage scenarios. A single Vault can contain several logical vaults with distinct data owners who can own and control their data via separate, externally held keys. This capability, known as Hold Your Own Key (HYOK), is extremely valuable as enterprise data flows to partners and suppliers.

In addition to supporting traditional tokenization features such as swapping sensitive data for tokens, and detokenizing or releasing clear text when asked; Titaniam Vault truly changes the tokenization paradigm by delivering the following additional capabilities:


  • Data Types & Context: In addition to tokenizing individual data items, Titaniam Vault supports full data context via documents and collections; structured and unstructured data; binaries and tags; and field, index, collections, file, and schema-level security.
  • Search & Analytics: Supports full-featured search and analytics without detokenization; search through unstructured data; and fuzzy search such as Soundex. It includes full-text search, including prefix, suffix, wildcard, etc.
  • Data Privacy: Releases data in all nine privacy-preserving formats and enables secure data sharing with partners and suppliers. It supports granular field-level privacy policies and private data sharing across vaults or applications.
  • Encryption Keys / HYOK: Integrates with industry-leading key vaults for key materials and supports Bring Your Own Key (BYOK) and Hold Your Own Key (HYOK) at scale and zero downtime key rotation and re-keying. It is also resilient against compromised master keys and certified for NIST FIPS 140-2 Key Derivation protocols.
  • Integration & App Development: Integrates with existing application role-based access control (RBAC), seamlessly interoperates with other Titaniam models to expand coverage and supports developer-led security with the direct development of new applications on top of the vault. It can be deployed alongside any cloud or on-prem datastore and is supported on all major cloud platforms.
  • Certification, Compliance & Post-attack Support: Provides visibility into data observed, accessed, or exfiltrated in an attack and post-attack evidence of compliance and certification. NIST FIPS 140-2 validated with all individual algorithms NIST CAVP certified.

Titaniam, which announced its vault and full product suite in March 2022, utilizes a continuous deployment model. In addition to cutting-edge encryption-in-use, Titaniam differentiates itself by providing functional capabilities equivalent to at least three other categories of data protection solutions. Titaniam is orders of magnitude faster than its closest competitors and provides unprecedented data security coverage at a fraction of the cost, making it one of the most sensible solutions in the CISOs toolbox today.

To learn more about Titaniam Vault and the rest of its ever-improving product suite, go to Titaniam.io today.

ABOUT TITANIAM

Titaniam is the industry’s most advanced data security and ransomware defense platform that utilizes high-performance encryption-in-use to keep valuable data secure even if the enterprise is breached and its data stolen. With the ability to process data without decryption and support nine different privacy-preserving data formats, Titaniam is the market’s answer to address ransomware and extortion, insider threats, and data privacy enforcement. In addition to cutting-edge encryption-in-use, a single deployment of Titaniam provides the equivalent of three other categories of data security solutions. In the event of an attack, Titaniam offers auditable evidence that valuable data retained encryption throughout the attack, thus minimizing compliance as well as notification obligations. Titaniam is a Gartner Cool Vendor in Data Security, named vendor in Gartner Hype Cycle for Data Security, named Vendor in Gartner Hype Cycle for Data Privacy, Winner of four Global Infosec Awards ar RSAC2022, TAG Cyber Distinguished Vendor, and Intellyx Digital Innovator for 2022. To learn more, visit https://titaniam.io/

Share article on social media or email:

Oxford Performance Materials and SINTX Technologies Collaboration Yields Major Breakthrough in Orthopedic & Dental Coatings


Oxford Performance Materials, Inc. (OPM; https://oxfordpm.com/), an industry leader in advanced polymer science 3D-printed orthopedic devices and coating technologies, and SINTX Technologies, Inc. (https://sintx.com/; NASDAQ: SINT), an original equipment manufacturer (OEM) of advanced ceramic materials for medical and technical applications, announced their successful development of a new class of orthopedic coatings. These coatings are targeted at overcoming the clinical limitations of metallic implants, some of which have come under increasing scientific and regulatory scrutiny worldwide (see e.g., Biological Responses to Metal Implants (FDA 2019)).

SINTX and OPM combined their respective expertise in polymer and ceramic material science to create a novel composite coating technology that can be applied to biomedical metallic substrates. Silicon nitride (chemical formula Si3N4) and polyetherketoneketone (PEKK) polymer are biomaterials that already have FDA clearance for human implantation. OPM and SINTX jointly developed a suspension of PEKK and submicron silicon nitride powder that can be applied to titanium, as well as other metallic substrates used in modern orthopedic and dental surgery. The suspension is then cured to form a tough and tenaciously adherent composite film less than one micron in thickness. Further testing is underway toward submission of the technology for regulatory approval. Under a licensing agreement in place, either company can enter royalty-bearing commercial agreements with mutually selected customers.

“We began our work with SINTX with the goal of addressing several well-recognized clinical shortcomings of metallic implants that are widely used in orthopedics, dentistry, and other kinds of reconstructive surgery. For example, metal implants are susceptible to bacterial infection; when this occurs, the implants usually require surgical removal with considerable cost and patient morbidity. Also, the potential harmful effects from long-term exposure to metal ions arising from surface corrosion and degradation of metal implants are of growing concern. Third, bone ingrowth into porous metal implants, while generally reliable, can be delayed such that healing between metal and bone can be impeded, thus impairing outcomes from surgery,” said Scott DeFelice, CEO of OPM. “We wanted to address these clinical concerns using well-accepted biomaterials, enabled by a highly novel, cost-effective, and patented process technology that entirely encapsulates metal implants in a sub-micron layer of our PEKK polymer, enhanced with SINTX’s silicon nitride.”

SINTX’s CEO Sonny Bal added: “Having practiced orthopedic surgery, I am familiar with the advantages and limitations of metal implants and gratified that we have developed a new technology with OPM to improve implant performance. Metal implants are well-accepted by surgeons because of the proven durability of titanium, stainless steel, and cobalt-chrome, as evidenced by decades of clinical data. The PEKK-silicon nitride composite coating is very exciting because it adds to the proven attributes of metal implants by imparting bacterial resistance, speeding up bone ingrowth, and reducing metal ion exposure in the body. In the next phase of our collaboration with OPM, we will optimize the coating process, apply the coating to complex device surfaces, conduct rigorous chemical and biological evaluations with clinically relevant bacterial strains and bone cells, and undertake standardized testing protocols toward securing regulatory clearances and product claims. Initial industry response to our new technology has been very encouraging, and we see wide applications for OEMs, hospitals, and clinicians who have an interest in preventing post-surgical infections and enhancing bone integration. Representative target areas for the new composite technology include implants used in trauma reconstruction, hip and knee replacements, spine fusion, sports medicine, and dentistry.”

Unlike other technologies, the PEKK/Silicon Nitride composite coating does not rely upon the release of antibiotics or the presence of antibacterial materials, such as silver ions or peptides. Instead, the product leverages both passive and active surface mechanisms to discourage bacterial adhesion, while stimulating osteoblast cell interaction with bone. These properties are inherent to the biomaterials used and have been validated in a number of scientific findings and publications that have undergone rigorous peer review. In addition to testing protocols, the companies have begun initial application discussions with several orthopedic and dental OEM’s who are interested in evaluating commercial applications of the composite product on titanium, stainless steel, and cobalt chrome substrates.

For more information, please visit https://oxfordpm.com/ and https://sintx.com/.

About Oxford Performance Materials, Inc.

Oxford Performance Materials, Inc. was founded in 2000 to exploit and commercialize the world’s highest performing thermoplastic, PEKK (poly-ether-ketone-ketone). OPM’s Materials business has developed a range of proprietary, patented technologies for the synthesis and modification of a range of PAEK polymers that are sold under its OXPEKK® brand, including coating technologies for a range of industrial and biomedical applications. OPM is a pioneer in 3D printing. OPM’s OsteoFab® technology is in commercial production in numerous orthopedic implant applications, including cranial, facial, spinal, and sports medicine devices, and OPM’s OXFAB® production parts are designed for highly demanding industrial applications.

Business or Media Inquiries for Oxford Performance Materials:

Bernard Plishtin

Oxford Performance Materials, Inc.

917.494.3649

bplishtin@oxfordpm.com

About SINTX Technologies, Inc.

SINTX Technologies is an advanced ceramics company that develops and commercializes materials, components, and technologies for medical and technical applications. SINTX is a global leader in the research, development, and manufacturing of silicon nitride, and its products have been implanted in humans since 2008. Over the past two years, SINTX has utilized strategic acquisitions and alliances to enter into new markets. The Company has manufacturing facilities in Utah and Maryland.

For more information on SINTX Technologies or its silicon nitride material platform, please visit https://sintx.com/.

Forward-Looking Statements for SINTX Technologies, Inc.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA) that are subject to a number of risks and uncertainties. Risks and uncertainties that may cause such differences include, among other things: the collaboration with Oxford Performance Materials may not result in new and innovative products or an increase in revenue; the FDA may not clear any products for commercialization; the industry may not accept the new products or may turn to products they deem more effective or less expensive; patients may not realize the expected benefits of our products; volatility in the price of SINTX’s common stock; the uncertainties inherent in new product development, including the cost and time required to commercialize such product(s); market acceptance of our products once commercialized; SINTX’s ability to raise additional funding and other competitive developments. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management’s current estimates, projections, expectations, and beliefs. There can be no assurance that any of the anticipated results will occur on a timely basis or at all due to certain risks and uncertainties, a discussion of which can be found in SINTX’s Risk Factors disclosure in its Annual Report on Form 10-K, filed with the Securities and Exchange Commission (SEC) on March 25, 2022, and in SINTX’s other filings with the SEC. SINTX disclaims any obligation to update any forward-looking statements. SINTX undertakes no obligation to publicly revise or update the forward-looking statements to reflect events or circumstances that arise after the date of this report.

Business or Media Inquiries for SINTX:

SINTX Technologies

801.839.3502

IR@sintx.com

ProPharma Group Acquires OneSource Regulatory to Bolster its Regulatory Consultancy Services


ProPharma Group

ProPharma Group

“The partnership with OneSource Regulatory is a critical step in reinforcing ProPharma Group as a worldwide leader in providing end-to-end solutions to the pharmaceutical, biotech, medical device, and diagnostic industries,” said ProPharma Group’s CEO, Michael Stomberg.

ProPharma Group’s acquisition of OSR is an advancement in its dynamic growth strategy, focused on combining best-in-class services and solutions to the life sciences industry. OSR strengthens ProPharma Group’s portfolio of services with their stature as a market leader in support services that span from pre-launch, launch and post-approval across the entire product lifecycle.

“The partnership with OneSource Regulatory is a critical step in reinforcing ProPharma Group as a worldwide leader in providing end-to-end solutions to the pharmaceutical, biotech, medical device, and diagnostic industries,” said ProPharma Group’s CEO, Michael Stomberg. “The addition of OSRs leadership and expertise expands ProPharma Group’s capabilities around regulatory compliance and extends our regulatory offerings further into the commercialization lifecycle. Working together will accelerate the success and operational excellence of our clients globally. We are excited to see what the future holds for OneSource Regulatory and ProPharma Group.”

“We are thrilled to join ProPharma Group,” said Tracy Rockney, J.D. “Together, we provide a truly unique consultancy offering to the life science industry. With our combined capabilities, clients know they are working with a leading partner that they can trust to deliver. The healthcare sector is so important to our everyday lives—now more than ever—and both PPG and OSR are dedicated to continually supporting this mission with our effective full product lifecycle solutions.” In addition to services, the OSR team brings innovative technology solutions. According to Robert Merrill, J.D., “We are extremely excited to join ProPharma Group where we will have a broader opportunity to deploy our technology solutions along with their worldwide services, as well as leveraging their expertise to enhance our technology solution development.”

Since partnering with Odyssey Investment Partners in October 2020, ProPharma Group has made significant acquisitions in the regulatory, quality and compliance, and medical information and pharmacovigilance space, including the most recent acquisition of M Squared Associates – specializing in devices, biologics, and combination products for a wide range of therapeutic areas and disease spaces.

Edgemont Partners – Healthcare Investment Bank, acted as the exclusive financial advisor to OneSource Regulatory.

About ProPharma Group

ProPharma Group is the global, independent, single-source provider of regulatory, clinical, and compliance services serving pharmaceutical, biotechnology, and medical device companies. Founded in 2001, ProPharma Group has more than 2800 colleagues worldwide providing solutions to complex challenges in a dynamic regulatory environment. With the mission to improve the health and safety of patients, ProPharma Group is focused on delivering the highest quality services throughout the full product lifecycle including regulatory sciences, clinical research solutions, life science consulting, R&D technology, pharmacovigilance, and medical information services. For more information, please visit http://www.propharmagroup.com.

About OneSource Regulatory

Established in 2015, OneSource Regulatory and OneSource Regulatory Technology, headquartered in McKinney, Texas,, provides pre- and post-approval regulatory, medical and marketing operations services across the product development and commercial lifecycle as well as innovative technology solutions. The company’s core services include:


  • Advertising and Promotional Review Support – expert medical and regulatory review services to ensure that marketing and medical materials are scientifically accurate, compliant and competitive, while achieving and surpassing business needs.
  • Marketing Operations – providing support to review teams by streamlining the review, approval, and execution of promotional and medical materials in addition to providing expert services to advertising agencies.
  • Regulatory Affairs Support – strategy, labeling, and CMC support services across all phases of development, including NDA and BLA submission planning and execution.
  • Regulatory Operations – process optimization and system implementation for document management, archiving, and publishing across submission types.


The technology solutions are focused on providing answers and information that can improve regulatory and commercial outcomes.

About Odyssey Investment Partners

Odyssey Investment Partners, with offices in New York and Los Angeles, is a leading private equity investment firm with more than a 25-year history of partnering with skilled managers to transform middle-market companies into more efficient and diversified businesses with strong growth profiles. Odyssey makes majority-controlled investments in industries with a long-term positive outlook and favorable secular trends. For further information about Odyssey, please visit http://www.odysseyinvestment.com.

Share article on social media or email:

Everest Rehabilitation Hospitals Announces Plans to Construct a 36-Bed Physical Rehabilitation Hospital in “The Villages” Florida (their eighth location in the state)


News Image

“We firmly believe that patients thrive exponentially when their environment and their level of care far exceed their expectations.“

Today, Everest Rehabilitation Hospitals announced plans to construct a 36-bed inpatient physical rehabilitation hospital in The Villages, FL. This will be Everest’s eighth location in the state of Florida with locations already in S. Orlando (Kissimmee), E. Lakeland/Winter Haven, W. Orlando (Ocoee), St. Pete, Viera, Port Charlotte and Ocala, Florida.

Everest Rehabilitation Hospital’s standalone comprehensive physical rehabilitation hospital will be constructed on 8.47 acres of land located at US Highway 301 in Oxford, FL. The $24M project is the latest in Everest’s construction of identical hospitals. Everest is known for its unmatched physical rehabilitation patient care and for developing identical, modern, 40,000 square foot, 36-bed, single story physical rehabilitation hospitals. With each of the 36 private rooms complete with contemporary art, 65” flat screen TVs and a private spacious bathroom, staying at Everest’s hospitals are more compared to a luxury hotel versus a typical hospital setting. Everest Rehabilitation Hospitals are predesigned with an option to add an additional 17 private rooms should the market dictate the need for expansion.

To better serve the needs of patients, Everest Rehabilitation Hospitals include spacious, technologically advanced equipped inpatient and outpatient physical therapy gyms, a large outdoor mobility courtyard for therapeutic use, state-of-the-art aqua therapy, a completely furnished life skills training apartment with a full kitchen and bathroom, in-house dialysis, and an in-house pharmacy. Everest understands the importance of the support system surrounding the patients as well. Included in the facility are several family gathering areas, an extra-large dining hall and an outdoor patio. The hospital will serve patients recovering from stroke, brain injury, neurological conditions, trauma, spinal cord injury, speech impediments, amputation, pulmonary disease, orthopedic injury, COVID-19, and other medically complex conditions.

Everest Rehabilitation Hospital in The Villages, Florida will create over 100 jobs and provide for an $8 million-dollar a year payroll to the community. Bringing a high-end comprehensive acute care physical rehabilitation hospital to Sumter County is so exciting. “We are ecstatic for the opportunity to serve The Villages, Oxford, Wildwood, Lady Lake, Fruitland Park, Leesburg, Lake Panasoffkee and the surrounding communities. We absolutely believe that patients thrive when their environment and their level of care surpass their expectations. The level of care in our acute physical rehabilitation hospital setting cannot be provided at other levels of care such as skilled nursing facilities (SNF). The average length of stay at a comprehensive inpatient rehabilitation hospital is one-third of a typical stay at a skilled nursing facility with far better results.” Jay Quintana, Everest Rehabilitation’s CEO said. “We provide one to one physical therapy, five to seven days a week, daily medical visits by rehabilitation physicians and a strong 24 hour a day nurse to patient ratio that contributes to optimal outcomes and the highest quality of care.”

Everest Rehabilitation Hospital The Villages will feature an interdisciplinary physician-led experienced team of rehabilitation therapists focused on increasing patient strength and endurance and improving quality of life in a modern, state of the art setting.

About Everest Rehabilitation Hospitals, LLC

Everest Rehabilitation Hospitals LLC, based in Dallas, Texas, is a multispecialty acute care physical rehabilitation hospital company focused on providing high quality, physical rehabilitation care. Everest is passionate about patient care; striving to create healing and nurturing environments for all patients that not only meet their medical needs but address their emotional and social needs as well. Patients are guided through the necessary steps to reclaim daily life, recover function, and return to an optimal quality of life by combining the latest treatments, technologies, and research with a unique interdisciplinary team approach involving the patient and family from day one. Everest provides the highest level of care available to patients with disabilities caused by injuries or illnesses, or from traumatic accidents.

http://www.everestrehab.com

Jay Quintana, CEO/ Co-Founder

Jquintana(at)everestrehab.com

469-713-1145

Share article on social media or email:

U.S. Oral Surgery Management Announces First Partnership in Michigan


USOSM now has partner practices spanning 20 states.

The doctors of Oral and Facial Surgeons of Michigan are synonymous with excellence. They’ve developed a well-deserved reputation for exceptional skill and compassion, listening to their patients and helping them to feel at-ease during both complex and simple procedures.

U.S. Oral Surgery Management (USOSM) – a specialty management services company that exclusively serves premier oral and maxillofacial surgeons – is excited to announce a partnership with Oral and Facial Surgeons of Michigan, an oral and maxillofacial practice with four locations in southeast Michigan. Headquartered in Irving, Texas, this is USOSM’s first partner practice in the state.

“This is our first partnership in Michigan, and we’re honored to announce that it is with Oral and Facial Surgeons of Michigan, which is one of the top OMS (oral and maxillofacial surgery) specialists in the state,” said Richard Hall, USOSM president and CEO. “The doctors of Oral and Facial Surgeons of Michigan are synonymous with excellence. They’ve developed a well-deserved reputation for exceptional skill and compassion, listening to their patients and helping them to feel at-ease during both complex and simple procedures.”

As its new partner, USOSM will provide Oral and Facial Surgeons of Michigan with “behind-the-scenes” support services, such as HR, technological support and negotiations of third-party payment schedules. Like all of USOSM’s partner practices, Oral and Facial Surgeons of Michigan will retain complete clinical autonomy.

Oral and Facial Surgeons of Michigan has locations in Brighton, Clarkston, Hartland and Waterford. The practice has six doctors, who provide a full-scope of OMS services from dental implants and wisdom tooth removal to corrective jaw surgery and the diagnosis and treatment of facial pain/injuries.

“Over the years, our practice has developed a reputation of setting the benchmark both clinically and from a business standpoint,” said Dr. Bryan Johnson, the senior partner at Oral and Facial Surgeons of Michigan. “The changing landscape as it pertains to OMS is one of the driving factors behind this partnership. We want to continue to be the best in this business. USOSM has the resources and the strength to help us achieve our goals.”

Headquartered in Irving, Texas, USOSM has partner practices spanning 20 states. They include Texas, Colorado, Georgia, Tennessee, Minnesota, Alabama, Oklahoma, Louisiana, South Carolina, Mississippi, Florida, Indiana, Kentucky, Arizona, California, Oregon, Virginia, Washington, Massachusetts and Michigan. A shared services organization, USOSM collaborates with premier oral and maxillofacial surgeons to offer a partnership solution for continued and accelerated practice success. USOSM provides operational, marketing and administrative support services, reinvests resources, and applies best practices to improve clinical and financial performance and produce steadier, more profitable growth for all. For more information, visit https://www.usosm.com/.

Share article on social media or email:

GTMRx Adds Former Medical Practice Lead for American College of Physicians to National Physician Advisory Group


News Image

Dr. Barr has deep experience in the medical field, and also in the healthcare consulting world – his commitment to making measurable improvements in healthcare delivery are an ideal fit for our mission.

Today, The Get the Medications Right™ (GTMRx) Institute, a coalition of over 1,600 members calling for medication management reform bringing together critical stakeholders across health care, is announcing the addition of Michael S. Barr, MD, MBA, MACP, FRCP, as the Institute’s Executive Physician Advisor. He will also be joining the GTMRx Physician Advisory Board. Dr. Barr has a broad and varied background in both medical and industry leadership positions, currently serving as the founder and President of MEDIS, a healthcare consulting company. Previously, Dr. Barr spent time with the American College of Physicians (ACP) as their Senior Vice President of Medical Practice and as an Executive Vice President with the National Committee for Quality Assurance (NCQA) ​​.

“Dr. Barr has deep experience in the medical field, and also in the healthcare consulting world – his commitment to making measurable improvements in healthcare delivery are an ideal fit for our mission,” said Katherine H. Capps, co-founder and executive director at GTMRx. “The work we do with physicians is crucial to ensuring a safe and effective medication use process for all consumers,” she said. “Michael understands that advanced primary care payment models function best when interprofessional teams are supported to deliver high-quality, comprehensive, person-centered services.”

One of the main aims of GTMRx is the advancement of comprehensive medication management (CMM), a systematic approach to medications where physicians and pharmacists ensure that medications are individually assessed to determine that each medication is appropriate, effective and safe for a patient. The GTMRx Physician Advisory Group plays a special role in this mission, providing leadership guidance and recommendations that help enable broad adoption of CMM throughout the continuum of care; they raise awareness and advocacy, getting buy-in from their physician colleagues, and help the organization view CMM through the eyes of a physician.

“I’ve spent so much of my career focused on advancing high-quality, equitable, and affordable healthcare for all and making measurable improvements in healthcare delivery; proper medication management is core to those aims,” said Dr. Michael Barr, MD, MBA, MACP, FRCP. “The work that GTMRx is doing to advance team-based, interprofessional care inclusive of clinical pharmacists providing CMM is vital to healthcare quality, equity, and delivering on the expectations of value-based payment models. I look forward to being part of it.”

While physicians provide a crucial lens into the medication management reform process, the GTMRx Institute’s membership includes members from all reaches of the healthcare profession that provide equally important perspectives. Pharmacists, nurses, patients, health IT innovators, drug and diagnostics companies, consumer groups, employers and payers all play important roles in GTMRx’s mission and work.

For more information on The GTMRx Institute, visit: https://gtmr.org/.

About the Get the Medications Right™ Institute

The GTMRx Institute is a catalyst for change that brings critical stakeholders together, bound by the urgent need to get the medications right. We are physicians, pharmacists, nurses, patients, health IT innovators, drug and diagnostics companies, consumer groups, employers, payers — aligned to save lives and save money through comprehensive medication management. By showcasing evidence and innovation, we motivate practice transformation and push payment and policy reform. Together, we ACT to champion appropriate, effective, safe and precise use of medication and gene therapies. Learn more at gtmr.org.

###

Media Contact:

Aimee Eichelberger

Aimee (at) superior (dot) com

312.952.1528

Share article on social media or email:

A-Alpha Bio Announces Collaboration with Bristol Myers Squibb to Discover Molecular Glue Targets for Protein Degradation


A-Alpha will identify and characterize novel pairs of E3 ubiquitin ligases and targets that Bristol Myers Squibb will utilize for potential design and development of molecular glues to induce targeted protein degradation.

A-Alpha Bio (A-Alpha), a synthetic biology and machine learning company that measures and engineers protein-protein interactions today announced a collaboration with Bristol Myers Squibb to discover molecular glue targets for protein degradation. A-Alpha will identify and characterize novel pairs of E3 ubiquitin ligases and targets that Bristol Myers Squibb will utilize for potential design and development of molecular glues to induce targeted protein degradation.

The collaboration is the second announced by A-Alpha in the rapidly growing field of targeted protein degradation. Under the agreement, A-Alpha will apply its AlphaSeq and computational platforms to quantitatively measure and analyze protein-protein binding between members of A-Alpha’s proprietary library of E3 ligases. As part of the agreement, A-Alpha Bio will receive upfront and near-term success payments and will be eligible for development milestones and a royalty on product sales.

Targeted protein degradation is an emerging therapeutic modality enabling potential therapeutic intervention otherwise difficult with conventional approaches. A-Alpha’s proprietary platform, AlphaSeq, is uniquely suited to detect weak protein-protein interactions that can be exploited for the discovery of molecular glues.

“We are excited to work with BMS to unlock the next generation of undrugged targets by broadening the search with more E3 ligases and enabling the rational discovery of molecular glues,” said David Younger, PhD, Co-Founder and CEO of A-Alpha Bio. “BMS is a pioneer and market leader in targeted protein degradation with marketed products and a strong development pipeline. We are confident that the insights we provide with our AlphaSeq platform and library of E3 ubiquitin ligases will enable BMS to discover high-impact medicines.”

To learn more, please visit: https://www.aalphabio.com/.

Share article on social media or email:

Personalized Wellness App gWell Featured on TV Series ‘Viewpoint with Dennis Quaid’


“The fact that gWell and the work that you are doing to impact the health and wellness of individuals and their families, on a personal level and in real time, is reaching a broader audience through national public television is super exciting to see.” says Dr. Calum MacRae.

Released to public television stations nationwide, ​​one of Viewpoint with Dennis Quaid’s latest short episodes features gWell, Inc., “a Boston-based healthcare and technology startup designed to help people take a more proactive stance to managing their health and well being,” in a series titled: “Future of Healthcare – Leading Innovation in Personalized Wellness Solutions”.

The award-winning ​​Viewpoint series with Dennis Quaid specializes in short-form educational stories. Each story highlights industry professionals and groundbreaking organizations.

Founded by physicians with decades of experience in designing and implementing personalized healthcare solutions, gWell’s technology (including an application, live coaching, and clinician portal) helps to bridge the gap between healthcare providers and individuals. Bringing advancements in DNA science to individuals in an affordable and accessible solution (analysis is FSA/HSA eligible), gWell helps people learn what they may be at risk for, prevent future pain and injury in their bones, muscles, and joints, and achieve better overall health and wellness.

A full six-minute feature can be viewed at gWellhealth.com/Viewpoint or on gWell’s YouTube channel. The video, produced with the Viewpoint creative team, features interviews from founder and CEO Dr. Surya Singh, gWell Chief Medical Officer and co-founder Dr. Chester Hedgepeth and gWell strategic advisor and co-director of the Genomic Medicine Program at Brigham and Women’s Hospital, Dr. Calum MacRae.

The segment highlights the groundbreaking work gWell is undertaking in personalized medicine. Dr. Calum MacRae says, “The fact that gWell and the work that you are doing to impact the health and wellness of individuals and their families, on a personal level and in real time, is reaching a broader audience through public television is super exciting to see.”

Viewpoint is dedicated to the mission of developing and distributing social and educational programming about our neighbors, our community, and world. Each story has one thing in common – changing our lives for the better.

This mission aligns well with gWell’s. “At the most fundamental level, gWell is focused on individual empowerment – enabling optimization of health and wellness, performance, and meaningful longevity.” says Dr. Singh.

The three physicians and personalized wellness proponents featured in the gWell segment will meet again to discuss being interviewed for the piece, why being featured on Viewpoint is important, and what they hope viewers will take away from watching it, in the upcoming episode of the podcast ‘Be well with gWell’, which you can find at gWellhealth.com/podcast.

Share article on social media or email:

Beyond Buzzwords, Upcoming Webinar Hosted by Xtalks


Join the featured speakers for an in-depth, interdisciplinary panel discussion of research leaders and community advocates from BridgeBio, the Duke ALS Clinic, RARE-X and The Sumaira Foundation

The rarity of each individual rare disease introduces many unique challenges and complexity in clinical research including barriers to achieving representative trial populations and equitable access to trials. Focused effort and dedicated action are essential to create an equitable clinical research environment.

Join the featured speakers for an in-depth, interdisciplinary panel discussion of research leaders and community advocates from BridgeBio, the Duke ALS Clinic, RARE-X and The Sumaira Foundation to learn about: Barriers and effective strategies to mirroring the patient community make-up in rare disease clinical trials; Challenges that rare disease Patient Organisations are tackling to improve diversity, equity and inclusion (DE&I) in their own communities; And consequences of getting it ‘wrong’ in the clinical stage and beyond.

Industry expert Laura Iliescu MSc, Director, Patient Advocacy Strategy, ICON will be moderating the panel which includes Dr. Richard Bedlack, MD, PhD, Professor of Neurology at Duke and Director of the Duke ALS Clinic; Jocelyn Ashford, Head of Cardiorenal Global Patient Advocacy, BridgeBio; Teneasha Washington, PhD, MPH, Diversity Equity and Inclusion Lead, RARE-X; Louisa Roberts, VP Innovative Partnerships, ICON; Jessica Wessel, Associate Director Therapeutic Expertise, Center for Rare Diseases, ICON; and Sumaira Ahmed, Founder & Executive Director, The Sumaira Foundation, for the live webinar on Tuesday, September 13, 2022, at 10am EDT (3pm BST/UK).

For more information, or to register for this event, visit Diversity, Equity and Inclusion in Rare Disease Clinical Trials: Beyond Buzzwords.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

HASA HIE Changes Name to C3HIE: Connected, Collaborative, Community


News Image

“We are very excited about our new name and brand positioning,” said Phil Beckett, CEO of C3HIE. “Our vision is to create healthier and connected communities where the patient always comes first.”

HASA, a non-profit, community HIE in Texas, announced today that it has changed its name and brand identity to C3HIE to reflect its new vision of helping the healthcare community become more connected and collaborative.

Based around the themes of “Connected, Collaborative and Community,” C3HIE’s new mission is to bring these three elements to life by delivering the right data at the right time to care teams, regardless of geography or provider type, into their workflows – from one secure, trusted source.

“We are very excited about our new name and brand positioning,” said Phil Beckett, CEO of C3HIE. “Our vision is to create healthier and connected communities where the patient always comes first. To achieve this, our goal is to provide care teams with access to health data for making collaborative decisions for ensuring the best possible health outcomes.”

In addition to the rebranding, C3HIE now provides HIE solutions in over 128 counties in the state of Texas with 70 hospitals and over 3,000 physicians, as well as with physicians in California, Delaware, and Florida.

C3HIE’s heritage started in 2006 when it helped the San Antonio healthcare community with High Utilizers (HU) in the emergency rooms, and it evolved into being a full HIE in 2011. Within a few years, it expanded to Corpus Christi, west Texas, north Texas and the Dallas Fort-Worth areas. C3HIE has now expanded to other states.

“This new brand builds on our legacy and supports our expansion in areas outside of Texas,” added Beckett. “We hope to continue this growth and further democratize health data in new and innovative ways.”

About C3HIE

C3HIE is a Texas-based, multi-region collaboration building the safe and secure infrastructure between healthcare providers’ electronic health records (EHRs) making it possible to exchange information across differing platforms. C3HIE offers customized health data sharing and analytics solutions aimed at hospitals, providers, health plans and patients that include real-time alerts, historical and predictive analytics, a longitudinal patient health record and community resource collaboration. http://www.C3HIE.org

Share article on social media or email: